Paula S Lee

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program
    Paula S Lee
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    JSLS 13:467-72. 2009
  2. ncbi Medical and surgical treatment of placenta percreta to optimize bladder preservation
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Division of Maternal and Fetal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Obstet Gynecol 112:421-4. 2008
  3. ncbi Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Int J Cancer 126:1378-89. 2010
  4. ncbi Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
    BMC Cancer 10:237. 2010
  5. ncbi The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:314-9. 2011
  6. ncbi Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group s
    Elizabeth L Jewell
    Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 115:424-9. 2009
  7. ncbi Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC
    Am J Obstet Gynecol 205:143.e1-6. 2011
  8. ncbi Yin yang 1 modulates taxane response in epithelial ovarian cancer
    Noriomi Matsumura
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Mol Cancer Res 7:210-20. 2009
  9. ncbi Relationship between tamoxifen use and high risk endometrial cancer histologic types
    Amy E Bland
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:150-4. 2009
  10. ncbi Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007

Detail Information

Publications14

  1. ncbi Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program
    Paula S Lee
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    JSLS 13:467-72. 2009
    ..Our goal was to perform an early evaluation of the feasibility of training fellows in robotic-assisted gynecologic procedures at the outset of our incorporation of this technology into clinical practice...
  2. ncbi Medical and surgical treatment of placenta percreta to optimize bladder preservation
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Division of Maternal and Fetal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Obstet Gynecol 112:421-4. 2008
    ..Placenta percreta is associated with significant morbidity and mortality. Interventions are dictated by hemodynamic stability, desire to retain future fertility, and efforts to reduce surgical morbidity at time of delivery...
  3. ncbi Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer
    Paula S Lee
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Int J Cancer 126:1378-89. 2010
    ..04). MAL methylation status may therefore serve as a marker of platinum sensitivity while MAL protein may be a target for development of novel therapies aimed at enhancing sensitivity to platinum-based drugs in ovarian cancer...
  4. ncbi Expression signatures of TP53 mutations in serous ovarian cancers
    Marcus Q Bernardini
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, 600 University Avenue, Toronto, Ontario M5G2M9, Canada
    BMC Cancer 10:237. 2010
    ..Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease...
  5. ncbi The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study
    Angeles Alvarez Secord
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 123:314-9. 2011
    ..To elucidate the regulation of MASPIN expression in epithelial ovarian cancer (EOC) and associations with p53 status and MASPIN promoter methylation...
  6. ncbi Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group s
    Elizabeth L Jewell
    Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 115:424-9. 2009
    ....
  7. ncbi Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
    Jason C Barnett
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC
    Am J Obstet Gynecol 205:143.e1-6. 2011
    ..The objective of the study was to compare adverse event rates between laparoscopic vs open surgery for endometrial cancer...
  8. ncbi Yin yang 1 modulates taxane response in epithelial ovarian cancer
    Noriomi Matsumura
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27708, USA
    Mol Cancer Res 7:210-20. 2009
    ....
  9. ncbi Relationship between tamoxifen use and high risk endometrial cancer histologic types
    Amy E Bland
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 112:150-4. 2009
    ....
  10. ncbi Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    DUMC 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 106:221-32. 2007
    ....
  11. ncbi Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 122:467-72. 2011
    ..To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer...
  12. ncbi Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 17:585-93. 2008
    ..The objective of this study was to determine whether cyclin E overexpression defines an etiologically distinct subgroup of ovarian cancer...
  13. ncbi Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy
    HISANI N HORNE
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Mol Cancer Res 7:199-209. 2009
    ..These data implicate MAL as a commonly altered gene in breast cancer with implications for response to chemotherapy...
  14. ncbi Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study
    Angeles Alvarez Secord
    Box 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 101:390-7. 2006
    ..This study examined MASPIN expression in human ovarian cancer, and explored the association between MASPIN and prognosis in patients with advanced stage disease treated with first-line cisplatin, carboplatin and/or paclitaxel...